Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGSNet product sales of FILSPARI ...

Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGS Net product sales of FILSPARI totaled $50 million in 4Q 2024; $132 million for full yea ...

Meet mild, reversible acute kidney injury (AKI) -- a sudden loss of kidney function that can go away within 24 hours or, if unchecked, can lead to chronic kidney failure, dialysis or transplant! It ...

S L E is a chronic multisystem autoimmune disease in which cardiovascular disease is a leading cause of mortality, with a ...